CD8A and lymphoma: Studies of CD19 CAR-T cells in an NSG mouse model of lymphoma have shown that TN and TCM produce a superior CAR-T product to TEM in terms of cytokine production (CD4+) and cytotoxicity (CD8+), and the potency of CD8+ CAR-T cells is enhanced by their production in the presence of CD4+ T cells [84].